ClinicalTrials.gg
RecruitingNCT06567015STX-241 FIHUpdated Sep 2, 2026

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

A Phase 1/2 interventional study of STX-241 in Non-small Cell Lung Cancer (NSCLC), sponsored by Pierre Fabre Medicament. Recruiting at 18 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
171
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 874 studies in Carcinoma, Non-Small-Cell Lung with a site in France — 169 open to participants now, 327 under way, 106 of them phase 3. Carcinoma, Non-Small-Cell Lung · France.

Planned enrollment
411th of 761
171 · median 190
Started
2024
with 62 others
Phase 1/2
81 of 874
28 open now
Primary completion
2027-11
later than 170 of 326 live
Registered
760th of 874
by date

Among the 874 studies in Carcinoma, Non-Small-Cell Lung with a site in France, this one is the 411th largest by planned enrollment of the 761 interventional ones that give a count, is one of 63 that started in 2024, is one of 81 in phase 1/2, reaches primary completion later than 170 of the 326 other live ones, and was the 760th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

169 of the 874 studies in Carcinoma, Non-Small-Cell Lung with a site in France are open now. Recruiting first, the newest first:

164 more — sign in →

All 169 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 874 studies in Carcinoma, Non-Small-Cell Lung with a site in France, or all of them as a file.
02

Study summary

The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241/PFL-241, a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, in participants with locally advanced or metastatic NSCLC that progressed during or following third generation EGFR TKI such as osimertinib due to C797X double acquired (secondary) mutations.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)

Keywords

  • non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated for participation in the trial obtained according to International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP), and national/local regulations.
  2. Male or female ≥ 18 years of age at the time of signing informed consent but at least of legal age in their country.
  3. Histological confirmation of locally advanced or , EGFR-mutant (ex19del or L858R mutations) non-small cell lung cancer (NSCLC) Stage IIIB/C or IV (AJCC 8th edition) not eligible for curative intent surgery or chemoradiation.
  4. Part 1 Disease progression on a 3rd generation EGFR TKI-based therapy (administered as monotherapy or in combination) received at any .

    Part 2: Disease progression after a 3rd generation EGFR TKI-based therapy (administered as monotherapy or in combination) given as first or second line of systemic anti-cancer therapy and no more than 2 prior lines of systemic anti-cancer therapy.

  5. Tumor mutation profile:

    • Part 1 (backfilling component): Presence of C797X and absence of T790M mutations documented locally (as part of clinical practice) on a sample (blood or tissue) collected after progression on treatment with 3rd generation EGFR TKI.
    • Part 2: Presence of C79X mutation documented locally (as part of clinical practice) on a sample (blood or tissue) collected after progression on a 3rd generation EGFR TKI-based therapy.
  6. Part 1 (Backfilling component), Part 2: At least one measurable target lesion according to v1.1.
  7. (ECOG) performance status 0-1.
  8. Adequate organ function as defined below:

    • (ANC) ≥ 1.5 x 10\^9/L
    • ≥ 75 x 10\^9/L
    • ≥ 90 g/L.
    • Serum total ≤ 1.5 x or ≤ 3.0 × ULN for participants with documented Gilbert's syndrome.
    • (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x ULN. If the participant has liver metastases, AST and ALT ≤5 × ULN.
    • Estimated (GFR) ≥ 50 mL/min by CKD-EPI equation
  9. Adequate cardiac function as defined below:

    • Mean corrected for heart rate according to Fridericia's formula (QTcF) value ≤ 470 msec for women and ≤ 450 msec for men and no history of long QT syndrome or risk factors for torsade de pointe.
    • (LVEF) ≥ 50% .
    • Systolic blood pressure \< 150 mmHg and diastolic blood pressure \< 100 mmHg
  10. Female participants of :

    • Negative highly sensitive serum β-HCG test performed within 7 days prior to first dose of STX-241 (C1D1) and a negative urine pregnancy test performed prior to C1D1.
    • Agreement to use one highly effective method (as defined in protocol and according to local regulations), starting at screening period, throughout the trial and until at least 182 days (i.e. more than 5 estimated STX- 241 half-lives (2 days) plus 6 months (180 days)) after the last dose of STX-241. If the highly effective method of contraception is a hormonal contraceptive method, it must be supplemented by one additional effective (barrier) method of contraception.
    • Agreement to not donate eggs (ova, oocytes) for the purpose of assisted reproduction during the trial and for a period of 182 days after the last dose of STX-241.

    Note: a female participant of childbearing potential is a woman who is not permanently sterilized or not (postmenopausal is defined as 12 months with no menses without an alternative medical cause).

  11. Male participants/partners with female spouse/partners of childbearing potential must agree to take appropriate precautions to avoid fathering a child, i.e.:

    • Consistently use a barrier method [e.g., condom with spermicidal foam / gel / film /cream/suppository], and his female partner use a highly effective method of contraception as defined in protocol and according to local regulations), starting at screening and continuing throughout the trial period and for 92 days (ie. more than 5 estimated STX-241 half-lives (2 days) plus 3 months (90 days)) after the last dose of STX-241.
    • Not donate sperm from Day 1 (first administration of STX-241) until at least 92 days after the last dose of STX-241.

NOTE: Other protocol defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  1. Part 1: Participants candidate for targeted therapies available to them (such as but not limited to therapies targeting ALK, BRAF, MET, NTRK, ROS1) as identified by local testing performed after progression to the last .

    Part 2: Participants candidate for targeted therapies available to them such as, but not limited to: ALK, BRAF, MET (ex14 mutation and amplification), NTRK, ROSI, (mutations and amplification) as identified by local testing performed after progression to 3rd generation EGFR TKI-based therapy.

  2. Part 2: Participants who received 1st or 2nd generation EGFR TKIs.
  3. Participant with rapid progressive disease eligible to receive a platinum-based chemotherapy.
  4. Participant unable ingest or digest tablets. This can be caused by any impaired gastrointestinal function or disease, such as for example: ulcerative diseases, malabsorption syndrome, small bowel resection, ileus, etc. or any condition causing uncontrolled nausea, vomiting or diarrhea.
  5. History of a primary other than NSCLC with the exception of:

    • Participants with a previous malignancy that completed all curative anticancer treatment at least 2 years before signing and with no evidence of residual disease from the prior malignancy at screening.
    • Malignancies with a negligible risk of or death (i.e. 5-year overall survival rate > 90%) that are adequately treated - Examples include, but are not limited to, completely resected basal cell carcinoma and squamous cell carcinoma of skin, melanoma in situ, curatively treated prostate cancer, breast cancer and early gastric cancer cured by endoscopic mucosal resection or endoscopic submucosal dissection.
  6. Spinal cord compression or that are associated with progressive neurological symptoms or require increasing doses of to control the CNS disease. If a participant requires corticosteroids for management of CNS disease, the dose must have been stable for 2 weeks prior to enrollment in the trial.
  7. History of to active or inactive ingredients of STX-241, or drugs with a similar chemical structure or from the same class.
  8. Active, bacterial, fungal, or viral infection, including, but not limited to: Virus (HBV), Virus (HCV), and known (HIV) or Acquired Immunodeficiency Syndrome (AIDS)-related illness, tuberculosis or an infection requiring systemic therapeutic treatment within 2 weeks prior to Day 1 (first administration of STX-241).

    Note: Participants with known HIV infection are permitted if they have controlled infection (undetectable viral load [HIV ribonucleic acid polymerase chain reaction (PCR)] and >350 either spontaneously or on a stable antiviral regimen). For participants with controlled HIV infection, monitoring will be performed per local standards.

  9. Positive SARs-CoV-2 or variants of SARs-CoV2 RT-PCR test or suspected to be infected with SARs-CoV2 or variants of SARsCoV2 with confirmation pending within 2 weeks of first dose of STX-241.
  10. Impaired cardiovascular function or cardiovascular disease (either active or within 6 months prior to signing informed consent), including any of the following:

    • Myocardial infarction, acute coronary syndromes including unstable angina, coronary/peripheral artery bypass graft, coronary angioplasty or stenting.
    • Symptomatic congestive heart failure ( Classification Class ≥ II).
    • Cerebrovascular accident or .
    • Symptomatic bradycardia, requirement for anti-arrhythmic medication.
    • Ongoing cardiac dysrhythmia of Grade ≥2.
  11. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situation that would limit compliance with trial requirements.
  12. Past medical history of Interstitial Lung Disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.
  13. Past medical history of Stevens-Jonhson Syndrome (SJS) or Toxic epidermal necrolysis (TEN) or any evidence of clinically active SJS/TEN.
  14. Women who are breast feeding.
  15. Prior anticancer therapy:

    • EGFR-targeted TKI within 7 days prior to the first dose of STX-241.
    • Any other systemic anticancer therapy within 28 days or 5 half-lives prior to the first dose of STX-241, whichever is the shortest, but with a minimum of 14 days in all circumstances.
    • Radiotherapy to a large field or including a vital organ (including whole brain radiotherapy or stereotactic radiosurgery to brain) within 14 days before the first dose of STX-241.
  16. received within 30 days prior to the first dose of STX-241.
  17. Any toxicities from prior therapy with a NCI-CTCAE Grade ≥1 at the time of the first dose of STX-241 (C1D1). Exceptions include alopecia (any grade), fatigue with a Grade ≤2, and peripheral neuropathy with a Grade ≤2.
  18. Major surgical procedure within 14 days of the first dose of STX-241 (procedures such as central venous catheter placement, tumor needle , and feeding tube placement are not considered major surgical procedures). Sequelae of surgical procedures must have resolved, including adequate wound healing, prior to the first dose of STX-241.
  19. Treatment with a prohibited medication or herbal remedy known to be strong CYP1A2 or inducers, strong CYP1A2 or CYP3A4 inhibitors, sensitive CYP1A2, CYP2B6 and CYP3A4 substrates, sensitive MATE1 and OATP1B1 substrates and proton pump inhibitors (PPI) and H2 antagonists unless discontinued prior to the first administration of STX-241 within the following timeframe:

    • At least 5 half-lives plus 14 days for strong CYP inducers.
    • At least 5 half-lives for CYP inhibitors, CYP/transporter substrates, proton pump inhibitor (PPI) and H2 antagonists.
  20. Participation in a clinical trial with administration of an drug within 5 half-lives plus 14 days of the investigational drug, before the first dose of STX-241.
  21. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e. g, could compromise the participant's well-being) or would prevent, limit, or confound the protocol-specified assessments.
  22. Employee or family member of the investigator or site staff.

NOTE: Other protocol defined exclusion criteria may apply.

Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
171 participants (estimated)

Study arms

  • Experimental
    STX-241/PFL-241

    Part 1: Dose Escalation and Backfilling components (Phase Ia) Participants will receive oral (PO) STX-241/PFL-241 twice daily (BID) at fixed doses: 10 mg, 20 mg, 40 mg, 80 mg, 120 mg, 180 mg on a continuous dosing schedule Part 2: Dose Range Optimization (Phase Ib). Participants will receive oral (PO) STX-241/PFL-241 twice daily (BID) at fixed doses selected from Part 1 within the OBD-MTD range for Part 2 on a continuous dosing schedule.

    Drug: STX-241

Interventions

  • DrugSTX-241

    Film-coated tablet Route of administration: Oral

    Also known as: PFL-241

06

What researchers measure

Primary outcomes

  1. Safety: Part 1 and Part 2: Safety: Incidence and severity of treatment emergent adverse events (TEAEs)/serious adverse events (SAEs), according to NCI-CTCAE v5.0 criteria.

    Time frame: Screening to Safety Follow-up (30 days post last dose)

  2. Part 1 and Part 2: Tolerability: Incidence of TEAEs/SAEs leading to STX-241 dose reductions, interruptions or discontinuations.

    Time frame: Screening to Safety Follow-up (30 days post last dose)

  3. Part 1: Maximum Tolerated Dose (MTD): Incidence of Dose-Limiting Toxicities (DLTs)

    Time frame: From first STX-241 intake until 28 days post first dose (28 days post first dose)

  4. Part 1: Optimal Biologically Active Dose (OBD)

    Time frame: From the first STX-241 intake up to 24 months

  5. Part 2: Recommended Phase II Dose (RP2D) of STX-241

    Time frame: From the first STX-241 intake up to 24 months

  6. Part 2: cORR (Confirmed Overall Response Rate) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 per investigator.

    Time frame: Up to 24 months

Secondary outcomes

  1. All Parts: PK exposure parameter: Maximum Plasma Concentration (Cmax)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  2. All Parts: PK exposure parameter: Time To Maximum Plasma Concentration (Tmax)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  3. All Parts: PK exposure parameter: Area Under The Plasma Concentration-Time Curve From Time Zero To Dosing Interval (AUC0-tau)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  4. All Parts: PK exposure parameter: Area Under The Plasma Concentration-Time Curve From Time Zero To Time With Last Measurable Concentration (AUC0-t)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  5. All Parts: PK exposure parameter: Area Under The Plasma Concentration-Time Curve From Time Zero To Infinity (AUC0-∞)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  6. All Parts: PK exposure parameter: Terminal Elimination Half-Life (t½)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  7. All Parts: PK exposure parameter: Apparent Terminal Elimination Rate Constant (λz)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  8. All Parts: PK exposure parameter: Apparent Clearance (CL/F)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  9. All Parts: PK exposure parameter: Apparent Volume Of Distribution (Vz/F)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  10. All Parts: PK exposure parameter: Peak Plasma Concentration (Cmax)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  11. All Parts: PK exposure parameter: Area Under The Plasma Concentration versus Time Curve (AUC)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  12. All Parts: PK exposure parameter: Trough Plasma Concentration (Ctrough)

    Time frame: Part 1 and Part 2: C1 Day 1, Day 2, Day 15; C2 Day 1; C3 Day 1; - each cycle is 28 days

  13. Part 1: cORR by Investigator Review (IR) in accordance to RECIST version 1.1.

    Time frame: Up to 24 months

  14. All parts: DCR (Disease Control Rate) by IR in accordance to RECIST version 1.1.

    Time frame: Up to 24 months

  15. All parts: TTR (Time To Response) by IR in accordance to (RECIST version 1.1.

    Time frame: Up to 24 months

  16. All parts: DOR (Duration of Response) by IR in accordance to RECIST version 1.1.

    Time frame: Up to 24 months

  17. Part 2: PFS (Progression-Free Survival) ( by IR in accordance to RECIST version 1.1.

    Time frame: Up to 24 months

  18. Part 2: Overall Survival

    Time frame: Up to 24 months

07

Study locations

18 of 18 sites recruiting
  • Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)
    Nashville, Tennessee 37203, United States
    Recruiting
    • Melissa Johnson, Dr. · Principal investigator
  • Oncology Consultants (OC) - Texas Medical Center - Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Julio Peguero, Dr · Principal investigator
  • Shanghai East Hospital, Tongji University
    Shanghai, 200120, China
    Recruiting
    • Caicun Zhou, Prof. · Principal investigator
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, 300060, China
    Recruiting
    • Huang Dingzhi, Prof. · Principal investigator
  • Centre Léon Bérard
    Lyon, 69008, France
    Recruiting
    • Aurelie Swalduz, Dr. · Principal investigator
  • CHU Hôpital de la Timone
    Marseille, 13385, France
    Recruiting
    • Pascale Tomasini, Dr. · Principal investigator
  • Institut de Cancérologie de l'Ouest (ICO) - René Gauducheau
    Saint-Herblain, 44800, France
    Recruiting
    • Sandrine Hiret, Dr. · Principal investigator
  • Institut Universitaire du Cancer de Toulouse - Oncopole
    Toulouse, 31059, France
    Recruiting
    • Julien Mazieres, Prof. · Principal investigator
  • Gustave Roussy
    Villejuif, 94800, France
    Recruiting
    • David Planchard, Prof. · Principal investigator
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 1307, Germany
    Recruiting
    • Martin Wermke, Prof. · Principal investigator
  • Netherlands Cancer Institute
    Amsterdam, 1066 CX, Netherlands
    Recruiting
    • Gerrina Ruiter, MD PhD. · Principal investigator
  • Hospital Quironsalud Barcelona
    Barcelona, 8023, Spain
    Recruiting
    • Alonso Guzman, Dr. · Contact
  • Vall d'Hebron Institut d'Oncologia
    Barcelona, 8035, Spain
    Recruiting
    • Enriqueta Felip Font, MD PhD. · Principal investigator
  • Hospital San Pedro
    Logroño, 26006, Spain
    Recruiting
    • Maria Jose de Miguel, Dr. · Contact
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
    • Javier de Castro Carpeno, Dr. · Principal investigator
  • Centro Intergral Oncologico Clara Campal (CIOCC) (START Madrid)
    Madrid, 28050, Spain
    Recruiting
    • Ramon Yarza, Dr. · Principal investigator
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
    Recruiting
    • Chi Chi Lin, Dr · Principal investigator
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
    Recruiting
    • Yung-Hung Luo, Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Pierre Fabre is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies as defined in our commitments. These requests are reviewed and approved by an independent review panel on the basis of scientific ground. All data provided if any is anonymized to respect the privacy of trial participants in line with applicable laws and regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: This trial data availability is according to the criteria and process described in our website

Data sharing details ↗ · clinicaltrials.pierre-fabre.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Nov 2027, 38 months after the start.

Of 311 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 38 months is below that.

Counting every sponsor, half of 434 studies reached it within 62 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2024
First posted
Aug 22, 2024
StartActual
Sep 17, 2024
Primary completionEst.
Nov 20, 2027
CompletionEst.
Jul 2030
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06567015
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Sep 17, 2024
Primary completion
Nov 20, 2027 (estimated)
Completion
Jul 2030 (estimated)
Last update
Sep 2, 2026

Study contacts

Data Protection Officer
Contact
dpofr@pierre-fabre.com
00 33 684752268

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion